BBIO ▲ +0.5% - BridgeBio Pharma, Inc.
$BBIO - Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
11-OCT-2026 02:30 PM ET
Share this post
More filings for $BBIO
BBIO ▲ +0.5% - BridgeBio Pharma, Inc.Oct 11, 2026BBIO ▲ +2.0% - BridgeBio Pharma, Inc.Oct 6, 2026BBIO ▲ +2.0% - BridgeBio Pharma, Inc.Oct 6, 2026BBIO ▲ +0.9% - BridgeBio Pharma, Inc.Oct 6, 2026BBIO ▲ +1.3% - BridgeBio Pharma, Inc.Oct 6, 2026BBIO ▼ -1.5% - BridgeBio Pharma, Inc.Oct 5, 2026
View full $BBIO filing history →💬 Comments
Loading comments…
Leave a comment